← All trials
NCT05654051
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2021
- Primary completion
- Aug 30, 2023
- Completion date
- Aug 30, 2023
- First posted
- Dec 16, 2022
- Last posted
- Dec 16, 2022
- Enrollment
- 51
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AIDS Clinical Trials GroupLead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of Texas at HoustonStudy chair
- University of ColoradoStudy chair
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.